PDS Biotechnology Corp
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
PDSB$1.03-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Common Stock | |||||
|---|---|---|---|---|---|
| Shares Issued | Amount | Additional Paid-in Capital | Accumulated Deficit | Total Equity | |
| January 1, 2025 | 37,987,380 | $12,536 | $201,103,311 | $(182,110,999) | $19,004,848 |
| Stock-based compensation expense | - | - | 1,253,882 | - | 1,253,882 |
| Issuance of common stock for consulting agreement | 150,000 | 50 | 203,451 | - | 203,501 |
| Issuance of common stock from at-the-market program, net | 205,350 | 68 | 306,047 | - | 306,115 |
| Issuances of common stock, net of issuance costs | 6,396,787 | 2,111 | 6,919,908 | - | 6,922,019 |
| Issuance of pre-funded warrants | - | - | 1,009,969 | - | 1,009,969 |
| Issuance of warrants | - | - | 2,150,771 | - | 2,150,771 |
| Exercise of pre-funded warrants | 706,334 | 233 | (162) | - | 71 |
| Net loss | - | - | - | (8,488,967) | (8,488,967) |
| Balance - March 31, 2025 | 45,445,851 | $14,998 | $212,947,177 | $(190,599,966) | $22,362,209 |
| Common Stock | |||||
|---|---|---|---|---|---|
| Shares Issued | Amount | Additional Paid-in Capital | Accumulated Deficit | Total Equity | |
| January 1, 2026 | 54,878,233 | $18,111 | $225,840,226 | $(216,606,504) | $9,251,833 |
| Stock-based compensation expense | - | - | 1,156,495 | - | 1,156,495 |
| Issuance of common stock for consulting agreement | - | - | - | - | - |
| Issuance of common stock from at-the-market program, net | 937,420 | 309 | 833,062 | - | 833,371 |
| Issuances of common stock, net of issuance costs | - | - | - | - | - |
| Issuance of pre-funded warrants | - | - | - | - | - |
| Issuance of warrants | - | - | - | - | - |
| Exercise of pre-funded warrants | - | - | - | - | - |
| Net loss | - | - | - | (7,349,056) | (7,349,056) |
| Balance - March 31, 2026 | 55,815,653 | $18,420 | $227,829,783 | $(223,955,560) | $3,892,643 |
Index
Condensed Consolidated
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.